Conference Series LLC invites all the participants across the globe to attend 12th World  Pharma Congress during October 16-18, 2017 Budapest, Hungary. Which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. Pharma Congress 2017 is a specially designed cluster Pharma conference. The main theme of this Pharma conferences is “Current Technologies & Advancements In Pharmaceutical Field’’. The Impact of developing and Marketing Drugs, its Registration & Approval” which covers a wide range of critically important sessions. 

Why to Attend???

Meet Your Target Market with members from around the world focused on learning about Pharma, this is your single best opportunity to reach the largest assemblage of participants from the Pharma community. Conduct demonstrations, distribute information, meet with current and potential Scientists, make a splash with a new research, and receive name recognition at this 3-day Pharmaceutical Event.World-renowned speakers, the most recent techniques, tactics, and the newest updates in Pharmaceutical Sciences fields are hallmarks of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event:

Target Audience:

• Professors, Associate Professors, Assistant Professors

• PhD Scholars

• Graduates and Post Graduates

• Directors, CEO’s of Organizations

• Association, Association presidents and professionals

• Noble laureates in Health Care and Medicine

• Bio instruments Professionals

• Bio-informatics Professionals

• Software development companies

• Research Institutes and members

• Supply Chain companies

• Manufacturing Companies

• CRO and DATA management Companies

• Training Institutes

• Business Entrepreneurr

Market Analysis

Over the last few decades a great deal of progress has  increased in research oriented approaches like improved technologies, developed infrastructures, and increased research in the field of Drug discovery, clinical trials, Drug delivery, preformulation studies and Nano-medicine in the pharmaceutical industry. To develop a new pharmaceutical formulation and to conduct clinical trials it cost at € 1,926 million in 2016. The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021. The new drug delivery system demand is increasing due to greater understanding of the functional benefits of excipients, pharmaceutical industry growth, and patent expiries of several popular drugs are positively impacting the overall growth of the market.

Revenue of the worldwide pharma market in 2016 was $1072bn. The global pharmaceutical industry was worth $10613bn in 2015. The generic pharma industry is currently worth an estimated $ 225 billion US and the largest four generic pharma companies worldwide by sales (Teva, Sandoz, Mylan, & Watson) account for nearly 50% of generic prescriptions in the US and 40% worldwide. The United Sates is a major hub for drug manufacturing and its market imports were valued over $86 billion in 2016, making the world’s largest importer of pharmaceuticals and $47 billion exports.

According to the 2015 EU Industrial R&D Investment Scoreboard the pharmaceutical and biotechnology sector amounts to 18.2% of total business R&D expenditure worldwide.On the other side Europe drug manufacturing is 225000 €millions and exports were 361500 €millions. Europe spent 31,500 €millions on R&D in 2015 while US spent 47,061€millions.However, considering the all aspects the European pharma market is expected to grow by 27% between 2015 and 2022.

Germany is forecast to have highest increase in market value at € 11.4bn. Novartis is forecast to reduce its R&D spending, from $10.5bn in 2020 to only $9.2bn in 2022. Of the top 20, Celgene and Regeneron are forecast to grow their R&D expenses most rapidly, with R&D spend forecast to increase 11% per year until 2022. Overall, total R&D spends is expected to increase by 2.8% each year, reaching $182bn in 2022.

Patient awareness regarding adverse drug events is stimulating global pharmacovigilance market growth by increase in number of National pharmacovigilance centers. Spain pharmacovigilance market size was valued over USD 230 million in 2015 and witness 10.2% CAGR from 2016 to 2024, to surpass USD 550 million by 2024.

Drug discovery technologies study includes Bio analytical Assays, Bioinformatics, Cell Based Assays, Genomic Technologies, High Throughput Screening, Proteomic Technologies and Others comprising Epigenetics, Metabolomics, Combinatorial Chemistry, Synthetic Biology, Systems Biology and Nanotechnology. The global market value for these technologies market with an expected share of about 30% in 2015 valued at $18 billion followed by Bioanalytical Assays or instruments by about $14 billion.

Innovative formulations are estimated to have contributed to 73%. Biopharmaceuticals have set new standards for popular drugs, which are traditionally defined as drugs that have $1 billion or more in annual sales; the top 15 biopharmaceutical products each profits annual revenue of more than $2 billion, with some drugs generating sales of more than $10 billion a year. In 2015 the top NMEs include Pfizer’s Ibrance, J&J’s Darzalex and Gilead’s Genvoya with a cumulative value of $32bn of sales expected in 2020. The increasing number of breakthrough therapy approvals also proves the ability of the pharmaceutical R&D to offer incremental benefits to targeted patient segments with larger unmet needs.